ArticleCureus2024
Higher Serum Dipeptidyl Peptidase-4 Activity in Newly Diagnosed Young-Onset Type 2 Diabetes Mellitus.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Dipeptidyl peptidase-4 (DPP4) enzyme inhibition is a therapeutic modality for type 2 diabetes mellitus (T2DM). However, its activity is insufficiently explored yet in youth-onset T2DM. Objective The objective of this study is to measure serum DPP4 enzyme activities in youth-onset T2DM and compare them with those in patients with normal glucose tolerance (NGT). Methods This cross-sectional study comprised 29 young participants with newly diagnosed untreated T2DM (age 24.5±4.5 years, range 13-30 years, 51.7% female) and an equal number of young participants with NGT (age 26.5±2.9 years, 48.3% female) screened by a two-sample 75gm oral glucose tolerance test. The relevant history of each participant was obtained, and the waist circumference, waist-hip ratio, blood pressure, and body mass index (BMI) were measured according to the standard procedure and recorded in the data collection sheet. Plasma glucose was measured using the glucose oxidase method, and serum DPP4 activity was measured using the colorimetry method. Results Participants with DM exhibited significantly higher serum DPP4 activity than NGT (DM vs. NGT: 481.4±70.4 pmol/min. vs. 420.3±49.2 pmol/min, mean±SD; p<0.001). A multivariate linear regression model adjusted for age, sex, BMI, and hypertension, found DM as an independent predictor for DPP4 activity (β=0.63.5, 95% CI 28.7-98.4, p=0.022). Conclusion DPP4 activity was significantly elevated in young participants with newly diagnosed T2DM. There might be a pathophysiological implication of DPP4 activity in young-onset T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.